BC282

BC282 is a humanized bispecific T-cell engager (T-BsAb) designed for the treatment of acute myeloid leukemia (AML). It simultaneously targets Interleukin-1 Receptor-Like 1 (IL1RL1, also known as ST2) and the CD3 epsilon subunit on T cells. IL1RL1 is highly expressed on leukemia stem cells (LSCs) and immunosuppressive cells within the bone marrow niche, such as regulatory T cells (Tregs), making it a dual-purpose target for eliminating both the "seed" (malignant stem cells) and the "soil" (the suppressive microenvironment). BC282 is constructed using the "da vinci" platform, which features a 2+2 IgG[L]-scFv format where two anti-CD3 scFv arms are attached to the carboxyl end of the light chains of an anti-IL1RL1 IgG. The antibody includes a silenced Fc domain (via N297A and K322A mutations) to prevent non-specific FcγR binding and complement activation, thereby improving T-cell trafficking and reducing toxicity. It was developed through a collaboration between researchers at the Medical University of South Carolina and Memorial Sloan Kettering Cancer Center.

Other names

anti-human IL1RL1 T-BsAbanti-hIL1RL1 T-BsAbanti-hIL-1RL1 T-BsAbanti-hIL 1RL1 T-BsAbanti-IL1RL1/CD3 bispecific antibodyhIL1RL1 T-BsAbhIL-1RL1 T-BsAbhIL 1RL1 T-BsAb